Association between treatment of superficial bladder cancer and 10‐year mortality in older adults with multiple chronic conditions

Multiple chronic conditions (MCC) are common among older patients with cancer; however, the exclusion of these patients from clinical trials has resulted in scarce knowledge concerning outcomes, resulting in variations in treatment. Superficial bladder cancer (SBC) disproportionately affects older adults, yet to the authors’ knowledge few studies to date have examined whether treatment improves long‐term survival. In the current study, the authors evaluated the association between treatment of SBC and 10‐year mortality in medically complex older adults.

[1]  Geoffrey E. Wile,et al.  NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  T. Garg,et al.  Burden of Multiple Chronic Conditions among Patients with Urological Cancer , 2018, The Journal of urology.

[3]  G. Guazzoni,et al.  Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project , 2018, The Journal of urology.

[4]  Courtney P. Williams,et al.  Most impactful factors on the health‐related quality of life of a geriatric population with cancer , 2018, Cancer.

[5]  Ilene G. Ladd,et al.  Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer , 2018, Bladder cancer.

[6]  Tyler J. VanderWeele,et al.  Sensitivity Analysis in Observational Research: Introducing the E-Value , 2017, Annals of Internal Medicine.

[7]  D. Ekwueme,et al.  Economic Burden of Chronic Conditions Among Survivors of Cancer in the United States. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Soloway,et al.  European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors. , 2017, Urology.

[9]  Sharon Kaasalainen,et al.  Managing multiple chronic conditions in the community: a Canadian qualitative study of the experiences of older adults, family caregivers and healthcare providers , 2017, BMC Geriatrics.

[10]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[11]  S. Halpern,et al.  States Worse Than Death Among Hospitalized Patients With Serious Illnesses. , 2016, JAMA internal medicine.

[12]  Traci C. Green,et al.  Counterfeit Medications and Fentanyl. , 2016, JAMA internal medicine.

[13]  M. Somerfield,et al.  Innovations in American Society of Clinical Oncology Practice Guideline Development. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Ekwueme,et al.  The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review , 2016, Expert review of pharmacoeconomics & outcomes research.

[15]  Peter C. Austin,et al.  Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis , 2016, Statistics in medicine.

[16]  Julia H. Rowland,et al.  Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[17]  M. Cooperberg,et al.  Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database , 2016, BJU international.

[18]  J. Moye,et al.  Health Values and Treatment Goals of Older, Multimorbid Adults Facing Life‐Threatening Illness , 2016, Journal of the American Geriatrics Society.

[19]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, JNCI Journal of the National Cancer Institute.

[20]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[21]  A. Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer , 2014, Cancer.

[22]  Susana B. Martins,et al.  Quality of Care for Patients with Multiple Chronic Conditions: The Role of Comorbidity Interrelatedness , 2014, Journal of General Internal Medicine.

[23]  A. Neugut,et al.  Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. , 2013, Journal of oncology practice.

[24]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[25]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[26]  Suzanne M. Miller,et al.  Cancer survivors and the patient-centered medical home , 2012, Translational behavioral medicine.

[27]  Marie Davidian,et al.  Doubly robust estimation of causal effects. , 2011, American journal of epidemiology.

[28]  A. Schaeffer,et al.  Introduction to the national urology research agenda: a roadmap for priorities in urological disease research. , 2010, The Journal of urology.

[29]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[31]  Edward L Spitznagel,et al.  Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.

[32]  M. Mamdani,et al.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. , 2004, JAMA.

[33]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[34]  Elizabeth H Bradley,et al.  Understanding the treatment preferences of seriously ill patients. , 2002, The New England journal of medicine.

[35]  T. Wilt,et al.  Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer. , 2000, The Cochrane database of systematic reviews.

[36]  Nancy Woods,et al.  Cancer and comorbidity , 2000, Cancer.

[37]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[38]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[39]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[40]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[41]  R. Millikan,et al.  Trends in stage‐specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006 , 2014, Cancer.

[42]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[43]  A. Holland,et al.  Agency for Healthcare Research and Quality: Health Literacy Universal Precautions Toolkit , 2013 .

[44]  N. Dubrawsky.  Cancer statistics , 2022 .